Exact Sciences is a company engaged in cancer screening and diagnostics solutions. It develops Cologuard, a patient-friendly non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also offers the Oncotype IQ genomic intelligence platform that is comprised of Oncotype DX gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced-stage prostate cancer.